Abstract Previous evidence from our laboratory showed that Epstein-Barr virus-immortalized lymphoblastoid B cells undergo a prominent down-modulation of HLA-II molecule expression when injected intraperitoneally in SCID mice, while HLA-I remains almost unaVected. Since this phenomenon can alter the experimental outcome of therapeutic protocols of adoptive cell therapy, we decided to evaluate the behavior of MHC antigens in a panel of cell lines belonging to the B-and T-cell lineages, as well as in epithelial tumor cell lines. Cells were administered in mice either intraperitoneally or subcutaneously and recovered 4 days later for HLA molecule expression analysis. Collected data showed a highly heterogeneous in vivo behavior of the various cell lines, which could alternatively downmodulate, completely abrogate or maintain unchanged the expression of either MHC-I or MHC-II molecules. Moreover, the site of injection impacted diVerentially on these aspects. Although such phenomena still lack a comprehensive clariWcation, epigenetic mechanisms are likely to be involved as epigenetic drugs could partially counteract MHC down-modulation in vivo. Nonetheless, it has to be pointed out that careful attention must be paid to the assessment of therapeutic eYcacy of translational protocols of adoptive immunotherapy, as modulation of MHC molecules on human target cells when transferred in a mouse environment could readily interfere with the desired and expected therapeutic eVects.
Introduction
The use of pre-clinical mouse models represents a common approach exploited to validate laboratory observations in vivo. These models allow to study disease states in ways that would be unfeasible in human patients or that would imply harm to be inXicted on humans.
In particular, the use of immunosuppressed mice inoculated with human tumor cell lines is widely exploited in tumor immunology, where they are used to test the eVects of diVerent therapeutic approaches, including protocols of adoptive cell therapy (ACT). In this regard, we previously reported results of pre-clinical ACT immunotherapy employing cytolytic CD4 + T cells directed to Epstein-Barr virus (EBV) antigens [1] . While these populations exerted a very relevant in vitro MHC-II-restricted cytotoxic activity against autologous EBV-transformed lymphoblastoid cell lines (LCL), nonetheless they disclosed a reduced in vivo eYcacy in comparison with their CD8 + EBV-speciWc counterpart. We found that expression of HLA-II molecules on LCL underwent a rapid down-modulation upon in vivo transfer. This phenomenon could be reverted by the in vivo use of a demethylating agent (decitabine) that signiWcantly restored the HLA-II expression on LCL [1] .
Here, we extended the analysis of the expression of MHC antigens on a panel of diVerent cell lines after ex vivo recovery following either subcutaneous (s.c.) or intraperitoneal (i.p.) administration, as such markers are critically involved in the interaction between eVector and target cells, and therefore, their modulation could strongly impact on the results of the experimental approaches of ACT.
Our results indicate that diVerent cell lines behave diVerently and that even the site of injection can inXuence the expression of HLA molecules in vivo. Since the expression of MHC-I and MHC-II can be under epigenetic control [2] , we assessed these aspects in our model using epigenetic drugs in vivo. Here, we provide evidence that one of the potential reasons for the observed down-modulation relies on epigenetic mechanisms, likely activated by the mouse microenvironment.
Based on these observations, we suggest that any ACT approach involving human tumor cell lines transferred in a mouse environment should be preceded by a careful analysis of MHC expression along tumor growth in vivo, since HLA antigen down-modulation could introduce a strong bias in the assessment of therapeutic eYcacy of adoptively transferred eVector T cells.
Materials and methods

Cell lines
The following human cell lines were used: DG-75, Daudi, Namalwa, and BL-41 are Burkitt lymphoma B cell lines; BL-41 B95.8 is the EBV-infected counterpart cell line; Raji is a lymphoblast-like cell line derived from a Burkitt's lymphoma; LCL is a lymphoblastoid cell line generated by EBV infection of PBMC; SH-9 is a lymphoblastoid cell line that spontaneously immortalized and derived from a Hodgkin's lymphoma patient; HuT-78 and Jurkat are T cell lymphoma cell lines; MOLT-3 and CEM are acute lymphoblastic leukemia T cell lines; IGROV-1 and OVCAR-3 are ovary adenocarcinoma cell lines; SK23-Mel, UACC-257, and A375 are malignant melanoma cell lines.
In vivo experiments
Six-to 8-week-old female SCID mice were purchased from Charles River Laboratories (Calco, Italy) and housed in our speciWc pathogen-free animal facility. Procedures involving animals and their care were in conformity with institutional guidelines (D.L. 116/92 and subsequent complementing circulars), and all experimental protocols were approved by the local ethical committee of Padova University (CEASA).
A total of 80-100 £ 10 6 cells from every cell line were injected i.p., while 20-25 £ 10 6 cells were used for s.c. injection. Four days later, the subcutaneous masses were recovered, mechanically disaggregated, and used for immunophenotyping. Similarly, i.p. injected cells were recovered by peritoneal washing and used for the Xow cytometry analyses. A high number of cells were required for the initial injection to provide the recovery of suYcient cells for subsequent staining and in vitro culture.
In vitro and in vivo treatment with epigenetic drugs Tumor cells explanted ex vivo were cultured in vitro with diVerent epigenetic drugs (trichostatin A and decitabine, also known as 2Ј-deoxy-5-azacytidine) that had already proven to be eVective in vitro [3, 4] or in vivo [1] . Cells were plated at 5 £ 10 5 cells/well in 24-well plate in complete medium (control) or medium added with trichostatin A (50, 250, and 500 nM, Sigma) or decitabine (1 M, Pharmachemie B.V., Haarlem, Holland), for up to 72 h. For in vivo experiments, mice were treated with trichostatin A (1 mg/kg once a day, days 0-3, Sigma [5] ), decitabine (0.25 mg/kg once at day 0, then twice a day, days 1-3 [1] ), suberoylanilide hydroxamic acid (SAHA, 1.25 mg/mouse, once a day, days 1-3, Alexis Biochemicals, Lausen, Switzerland [6] ), valproic acid (5 mg/mouse, once a day, days 1-3, modiWed from [7] , Sigma), and Interferon-(50,000 IU/mouse, once, 6 h before cells recovery, modiWed from [1] , PeproTech, Rocky Hill, NJ). On day 4, cells were recovered by peritoneal washing and used for the Xow cytometry analyses.
Flow cytometry analysis
Human cancer cells recovered ex vivo were initially gated according to their forward-and side-scatter proWles and then speciWcally identiWed for their human origin with antibodies to CD5 (for the MOLT-3 cell line; clone MEM-32, ImmunoTools, Friesoythe, Germany), CD19 (for all the B cell lines; clone 89B, Coulter, Milano, Italy), CD45 (for all the T cell lines, but MOLT-3; clone MEM-28, ImmunoTools), and CD44 antibody (for all the epithelial cancer cell lines; clone J-173, Immunotech Coulter, Milano, Italy). The gated populations always conWrmed to be 100% positive for the respective markers.
Further stainings were performed with antibodies to 2-microglobulin (clone 2M2, BioLegend, Cambridge, UK), HLA-I (HLA-A, HLA-B, and HLA-C loci, clone W6/32, BioLegend), HLA-A2 (clone BB7.2, BioLegend), HLA-II (clone Tü39, BD, Erembodegem, Belgium), HLA-DR (clone L243, BD; clone LN3, eBiosciences, San Diego, California, USA), HLA-DQ (clone HLADQ1, BioLegend; clone Tu169, BD), and PAN-Ig (Goat polyclonal anti-human IgG, IgA, and IgM (H+L), AbD Serotec, Oxford, UK). Control stainings were performed using the appropriate isotypes (mouse IgG1 for 2-microglobulin and HLA-DQ, BD; goat IgG for PAN-Ig, AbD Serotec; mouse IgG2a for all the other antibodies, BD).
To avoid potential bias in recognizing the implanted human cell lines, all antibodies were tested for cross-reactivity with mouse splenocytes and found negative.
After staining, red blood cells were lysed and cells were analyzed using FACSCalibur (BD) instrument and FlowJo software (TreeStar Inc., Olten, Switzerland).
Percentage of positivity was calculated as the diVerence between the positivity percentage of each marker and that of the corresponding isotype control.
Results
Based on our previous results [1] , Wrst we decided to extend the assessment of MHC-I and MHC-II expression, before in vivo administration and after ex vivo recovery, to a panel of B cell lines. Such analysis revealed that in all cases the percentage of positivity and the mean Xuorescence intensity (MFI) of samples were lower after ex vivo evaluation, but no general rule could be inferred. DG-75, SH-9, Raji (this latter being reported in Fig. 1a, b as an example of this group of cells), and Daudi (which does not harbor MHC class I) cell lines completely or partially down-modulated HLA-I and HLA-II molecule expression when injected i.p. On the other hand, most of the cell lines maintained a high expression of the analyzed markers when injected s.c., with the exception of LCL and, partially, SH9, Namalwa, and Daudi cell lines (LCL and Namalwa illustrate this behavior in Fig. 1b) . The only B cell lines that preserved the expression of MHC-I and MHC-II markers, after both i.p. and s.c. injection, were BL-41 and their EBV-infected counterpart (Fig. 1a, b) . Expression data obtained with pan anti-HLA-I were fully conWrmed by staining recovered cells with anti-2-microglobulin antibody (Fig. 1b) and anti-HLA-A2 allele-speciWc antibody (where present, data not shown). Similarly, results of cytometry analyses with the use of anti-HLA-DR and anti-HLA-DQ antibodies completely overlapped those obtained with pan anti-HLA-II (data not shown).
Interestingly, even the expression of surface immunoglobulins underwent down-modulation when injected i.p.
(especially in Raji cell line), while it was generally maintained after s.c. injection (Fig. 1b) .
When T cells were considered (Fig. 2a) , it turned out that the s.c. injection induced the partial down-modulation of MHC-I on all the lines we studied, except MOLT-3. The i.p. inoculation route aVected marker expression on MOLT-3 and HuT-78 cells but did not inXuence Jurkat and CEM cell lines. Finally, two ovarian carcinoma and three malignant melanoma cell lines were tested: IGROV-1 and OVCAR-3 tumors strongly down-modulated HLA-I expression after either i.p. or s.c. injection, while all melanomas retained MHC-I expression when injected i.p. but lost it after s.c. administration. (Fig. 2b shows only SK23-Mel, as an example of the behavior of the three melanoma cell lines.) Again, also in the case of both T cell and epithelial tumor cell lines, data of pan MHC-I and MHC-II expression were conWrmed by staining with anti-2-microglobulin and allele-speciWc antibodies (Fig. 2a, b and data not shown).
As some HLA-I and HLA-II promoters (and their transactivators) can be under epigenetic control [2] , host and tumor microenvironments might induce methylation and histone deacetylation in tumor cells, thus aVecting the expression of the MHC-I and MHC-II molecules [8, 9] . To evaluate this possibility, we cultured tumor cells explanted ex vivo with diVerent epigenetic drugs (namely, trichostatin A and decitabine) that had already proven to be eVective in vitro [3, 4] or in vivo [1] , respectively. Surprisingly, we observed that the simple placement of tumor cells in complete medium, without the addition of any drug, led to reversion of the down-modulated phenotype (when present) within a few hours (data not shown). To better clarify this issue, we decided to test the diVerent epigenetic drugs in vivo, in parallel with interferon-, a well-known inducer of MHC molecule expression. Mice were injected i.p. with tumor cell lines and treated with trichostatin A, decitabine, suberoylanilide hydroxamic acid, valproic acid, or Interferon-. As it can be appreciated in online resource, Supplemental Figure, 
Discussion
Adoptive cell therapy is regarded as an eYcient and promising approach for the treatment of diVerent tumors, ranging from several EBV-related malignancies [1, 10] to melanoma [11] . Before a new ACT protocol is accepted for clinical use, its eYcacy has to be demonstrated in animal models, mainly in mice injected with tumor cell lines to simulate the disease. While these models are generally accepted, notwithstanding they raise concerns regarding the cytokine milieu, the tumor microenvironment, the inoculation setting, and the life span of human-origin components that are transferred into the mouse, which can give rise to several biases ultimately perturbing the outcome [12, 13] . An example of such aspects can be found in a previous work from our group [1] where we assessed the therapeutic potentiality of EBV-speciWc CD4 + cytotoxic T cells, which were eVective in vitro, but not in vivo. We observed that LCL target cells, when injected in SCID mice, underwent a rapid HLA-II down-modulation, thus reducing the natural recognition of MHC-II peptide complexes by CD4 + CTL. Since this behavior was not observed in humans [1] , we concluded it was induced in the mouse model by some unidentiWed stimuli that could be partially overcome by using demethylating agents [1] . Based on such observation, we wondered whether this phenomenon was limited to LCL or could represent a more frequent occurrence. Therefore, we Wrst extended the panel of B cell lines tested that were analyzed 4 days after injection, because previous results showed that the maximal down-modulation was already reached at this time point [1] and maintained afterward (data not shown): results indicated that a recurrent behavior could not be established. Moreover, the site of injection had a profound inXuence on the observed down-modulation. In particular, with the exception of Namalwa, BL-41, and BL-41 B95.8 cell lines, all the other B cell lines down-modulated the expression of HLA-I and/or HLA-II when injected i.p., while the s.c. inoculation negatively impacted only on LCL, SH9, Daudi, and partially on Namalwa cell lines. Notably, surface immunoglobulin expression was also reduced in some cell lines and in a diVerential manner according to the injection site, when recovered ex vivo in comparison with in vitro culture.
Since no general rule could be extrapolated, we expanded our analysis to some T cell lines: again, no coherent behavior could be identiWed as HLA-I expression was totally abrogated in MOLT-3 and HuT-78, but not in Jurkat and CEM cell lines when injected intraperitoneally; the s.c. injection induced a partial down-modulation on all T cell lines, but the MOLT-3 cells. Finally, MHC class I expression on some epithelial tumor cell lines appeared undergoing a constant down-modulation, but even in this case with an exception represented by melanomas after i.p. injection.
Whereas the causes of such phenomena are not fully clariWed yet, nonetheless epigenetic mechanisms are likely to be involved, as supported by results we reported with epigenetic drugs; indeed, decitabine partially restored MHC-II expression in LCL cells, thus indicating that the methylation of promoters of genetic elements involved in the expression of HLA alleles may play an important role in MHC down-modulation [1] . On the other hand, trichostatin A counteracted HLA down-modulation in IGROV-1 cells, a Wnding suggesting that histone acetylation may represent an additional relevant mechanism, as previously reported in a diVerent setting [3] . These data are also in line with a previous study reporting an epigenetic eVect of the microenvironment, where bystander stromal cells may have a major inXuence on the growth and progression of tumors [14] . Moreover, in both the peritoneal cavity and, more pronouncedly, the inner mass of subcutaneous inoculi, tumor cells might undergo an hypoxic state, which has been already demonstrated to down-modulate HLA-G and MHC-I-related chain A (MICA) [15, 16] ; further, hypoxia has been also directly involved in MHC-I and MHC-II down-modulation in rat cells [17] .
In conclusion, no general rule regarding the maintenance or down-modulation of MHC-I or MHC-II molecules on human tumor cell lines upon in vivo transfer in immunodeWcient mice can be inferred by our data; indeed, every cell line appears to possess a particular behavior. These observations raise some important concerns about the interpretation of data resulting from the administration of human T cells into human-tumor-bearing mice, since negative results can be due to the absence of target molecules on the surface of cancer cells. Overall, our suggestion is therefore to check carefully the expression of MHC antigens on tumor cell lines upon their in vivo transfer before testing an ACT therapeutic protocol.
